Generate Biomedicines, Inc.
Generate Biomedicines, Inc. is a clinical-stage biotechnology company focused on using machine learning and generative biology to design novel protein therapeutics. The company’s Generate Platform combines computational design with biological engineering to create medicines across multiple protein-based modalities, including antibodies, enzymes, cytokines, peptides, and cell therapies. Its pipeline includes investigational programs such as GB-0895 for severe asthma, GB-4362, and GB-5267, reflecting its emphasis on developing treatments for complex and hard-to-address diseases. Based in Somerville, Massachusetts, Generate Biomedicines operates at the intersection of artificial intelligence, drug discovery, and therapeutic development, serving as a platform-driven innovator in modern biomedicine.
$12.09
-$0.97 (-7.43%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-737.04% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 55.9% YoY with margins expanding 225.6pp.
ROIC dropped from -202.13% to -255.26%, capital efficiency is deteriorating. Negative free cash flow of -$204M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$32M
▲ +55.9% YoY
Net Income (FY)
-$223M
▼ -22.9% YoY
Op. Margin
-737.04%
▲ +225.6pp YoY
ROIC
-255.26%
▼ -53.1pp YoY
Cash Flow & Balance Sheet
FCF (FY)
-$204M
▼ -68.4% YoY
Op. Cash Flow (FY)
-$201M
▼ -70.4% YoY
Net Debt
-$153M
Net Cash Position
Cash & Equiv.
$221M
Continue Research
Is Generate Biomedicines (GENB) overvalued?
Generate Biomedicines (GENB)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Generate Biomedicines scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Generate Biomedicines a high-quality business?+
Generate Biomedicines scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -737.0% operating margin and a -255.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Generate Biomedicines a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh GENB's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.